Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor

Executive Summary

Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.

You may also be interested in...



Organon Continues Building Women’s Health Portfolio With Forendo Buyout

The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

Organon Is Serious About Building A Women's Health Company, Deal By Deal

CEO Kevin Ali talked to Scrip about his plans for Organon, ahead of the spinout from Merck & Co. Women's health will be the top priority. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC144793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel